According to BioMarin Pharmaceutical's latest financial reports the company has HK$9.98 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-12-31 | HK$8.83 B | 5.32% |
2023-12-31 | HK$8.38 B | -16.89% |
2022-12-31 | HK$10.09 B | 27.64% |
2021-12-31 | HK$7.90 B | -4.28% |
2020-12-31 | HK$8.25 B | 40.68% |
2019-12-31 | HK$5.87 B | -30.86% |
2018-12-31 | HK$8.49 B | -22.15% |
2017-12-31 | HK$10.90 B | 78.11% |
2016-12-31 | HK$6.12 B | 33.32% |
2015-12-31 | HK$4.59 B | -37.35% |
2014-12-31 | HK$7.33 B | 20.48% |
2013-12-31 | HK$6.08 B | 75.31% |
2012-12-31 | HK$3.47 B | 129.07% |
2011-12-31 | HK$1.51 B | -28.97% |
2010-12-31 | HK$2.13 B | -8.5% |
2009-12-31 | HK$2.33 B | -46.11% |
2008-12-31 | HK$4.32 B | -5.26% |
2007-12-31 | HK$4.56 B | 103.24% |
2006-12-31 | HK$2.24 B | 506.27% |
2005-12-31 | HK$0.37 B | -2.32% |
2004-12-31 | HK$0.37 B | -76.28% |
2003-12-31 | HK$1.59 B | 177.25% |
2002-12-31 | HK$0.57 B | -43.56% |
2001-12-31 | HK$1.02 B | 226.03% |
2000-12-31 | HK$0.31 B | -35.92% |
1999-12-31 | HK$0.48 B | 571.9% |
1998-12-31 | HK$72.82 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() Ultragenyx Pharmaceutical RARE | HK$3.88 B | -61.14% | ๐บ๐ธ USA |
![]() Sangamo Therapeutics
SGMO | HK$0.19 B | -98.02% | ๐บ๐ธ USA |
![]() Esperion Therapeutics ESPR | HK$0.89 B | -90.99% | ๐บ๐ธ USA |
![]() Sanofi SNY | HK$67.86 B | 579.49% | ๐ซ๐ท France |
![]() Amicus Therapeutics
FOLD | HK$1.96 B | -80.31% | ๐บ๐ธ USA |
![]() Catalyst Pharmaceuticals CPRX | HK$4.55 B | -54.36% | ๐บ๐ธ USA |